

**Online Supplement Figure 1**. Diagram of an *ex vivo* intact heart seen by optical mapping camera. **A**, relative anatomical locations of the right ventricle (RV), the left ventricle (LV) and the left anterior descending artery (LAD). **B**, the preparation under the camera. **C**, an example of APD<sub>80</sub> map in the region of interest. The APD or Ca<sub>i</sub>TD are derived from the average value in the region of interest.



**Online Supplement Figure 2**. Apamin does not further prolong RR and QT intervals in male hearts with diLQTS. We included for analyses male hearts that maintained stable normal sinus rhythm throughout the study. **A** shows representative pseudo ECG traces of diLQT1 (HMR1556, 100 nmol/L), diLQT2 (E4031, 50 nmol/L), and diLQT 3 (ATX-II, 20 nmol/L). Apamin (100 nmol/L) was then given during continued drug infusion. **B**, linkage graphs show the changes of RR and QT intervals in different types of diLQTS. Asterisks indicate significant differences (\*diLQTS compared with baseline; p<0.05, each n=4-6).



**Online Supplement Figure 3**. Apamin does not further prolong APD<sub>80</sub> in male hearts pretreated with HMR1556. **A**, representative membrane potential traces and APD<sub>80</sub> maps at baseline and in the presence of HMR1556 (100 nmol/L), after apamin (100 nmol/L), and after washout (Protocol I, diLQT1). **B**, at 350 ms PCL, HMR1556 slightly prolonged APD<sub>80</sub> but no further increase of APD<sub>80</sub> was observed after apamin. **C**, summary of apamin effects on APD<sub>80</sub> at different PCLs in male rabbit ventricles. The apamin effects were not observed at any PCLs. Data presented as mean ± SEM. Asterisks indicate significant differences (\*diLQTS compared with baseline; p<0.05, n=5).



**Online supplement Figure 4**. Apamin does not further prolong APD<sub>80</sub> in male hearts pretreated with E4031. **A**, representative membrane potential traces and APD<sub>80</sub> maps at baseline and in the presence of E4031 (50 nmol/L), after apamin (100 nmol/L) and after washout (Protocol II, diLQT2). **B**, at 350 ms PCL, E4031 (50 nmol/L) significantly prolonged APD<sub>80</sub> but apamin did not cause further APD<sub>80</sub> prolongation. **C**, summary of apamin effects on APD<sub>80</sub> at different PCLs in male rabbit ventricles. The apamin effects were not observed at any PCLs. Data presented as mean  $\pm$  SEM. Asterisks indicate significant differences (\*diLQTS compared with baseline; p<0.05, n=6).



**Online Supplement Figure 5**. Apamin does not further prolong APD<sub>80</sub> in male hearts pretreated with ATXII. **A**, representative membrane potential traces and APD<sub>80</sub> maps at baseline and in the presence of ATX-II (20 nmol/L), after apamin (100 nmol/L), and after washout (Protocol III, diLQT3). **B**, at 350 ms PCL, ATX-II significantly prolonged APD<sub>80</sub> but without further increased APD<sub>80</sub> by apamin. **C**, summary of apamin effects on APD<sub>80</sub> at different PCLs in male rabbit ventricles. The apamin effects were not observed at any PCLs. Data presented as mean  $\pm$  SEM. Asterisks indicate significant differences (\*diLQTS compared with baseline; p<0.05, n=4).



**Online Supplement Figure 6.** Effects of apamin on action potential duration (APD) heterogeneity at PCL350 ms in female diLQTS ventricles. A, representative APD<sub>80</sub> maps at three diLQTS and after adding of apamin (100 nmol/L). The delta APD maps showed no large heterogeneities on the epicardium. B, apamin had no significant effects on the correlation of variance of APD<sub>80</sub> in female diLQTS ventricles.